Dr. Louis-Philippe Boulet, Université Laval, Québec, QC
Dr. Patrick Mitchell, University of Calgary, AB

Session Description and Learning Objectives – Dr. Louis-Phillipe Boulet
This talk will discuss the agreements in favour of ICS/SABA (Formoterol) on demand in mild asthma as in the GINA report.

At the end of this presentation, attendees will be able to:

  • Understand the historical background of GINA recommendations on mild to very mild asthma;
  • Know the current evidence supporting the above recommendations; and
  • Understand the limitations of these recommendations and need for additional studies.

Session Description and Learning Objectives  Dr. Patrick Mitchell
The preponderance of the evidence is that regular ICS (alone or in combination with formoterol) is the treatment of choice for mild asthma. My side of the debate shall rationally and empirically highlight that whilst superior to SABA usage in isolation it is inferior to regular ICS with a SABA as a reliver. The belief that as needed ICS/LABA to treat mild asthma is superior to low dose regular ICS as is evidenced by the clinical trials data and real world evidence reflect that this is just a cover up for poor compliance and not in fact a superior treatment.

At the end of this presentation, attendees will be able to:

  • Demonstrate that ICS is the backbone of asthma therapy;
  • Demonstrate that by tackling compliance, asthma outcomes would be improved; and
  • Refute the one-size-fits-all hypothesis for treating step 1 and 2 mild asthma.